SCHEMBL25229344

SCHEMBL25229344

CSc1ncc2cc(Oc3ccc([N+](=O)[O-])cc3)c(NCCO)nc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ LMNA P02545 5/20 0.41
▸ MAPT P10636 3/20 0.41
▸ THRB P10828 1/20 0.41
▸ PDE5A O76074 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ HPGD P15428 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HTT P42858 2/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ AKT1 P31749 1/20 0.35
▸ AKT2 P31751 1/20 0.35
▸ ABCG2 Q9UNQ0 1/20 0.35
▸ PDGFRA P16234 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ HSP90AA1 P07900 1/20 0.34
▸ HSP90AB1 P08238 1/20 0.34
▸ BCHE P06276 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29536685 0.80 ATM (0.43) LMNAMAPTALDH1A1HPGDHTT
SCHEMBL25227659 0.80 ATM (0.43) LMNAMAPTALDH1A1HPGDHTT
SCHEMBL29536776 0.76 MAPK8 (0.42) AKT1AKT2
SCHEMBL25222319 0.76 MAPK8 (0.42) AKT1AKT2
SCHEMBL29536877 0.73 HTT (0.41) LMNAMAPTHTTKMT2APDGFRA
SCHEMBL25225454 0.73 HTT (0.41) LMNAMAPTHTTKMT2APDGFRA
SCHEMBL29537098 0.73 MET (0.40) ALDH1A1AKT1AKT2KDR
SCHEMBL25227027 0.73 MET (0.40) ALDH1A1AKT1AKT2KDR
SCHEMBL25227024 0.71 AKT1 (0.39) LMNAMAPTALDH1A1HTTAKT1
SCHEMBL29536669 0.71 AKT1 (0.39) LMNAMAPTALDH1A1HTTAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
CN-116710453-A Kinase inhibitors and uses thereof 璧辰医药技术股份有限公司 2023-09-05 — — CN disclosed
EP-4192582-A1 KINASE INHIBITORS AND USES THEREOF ABM Therapeutics Corporation (US) 2023-06-14 — — EP disclosed
WO-2022032071-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORPORATION (US) 2022-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 TDP1 2898/4885TSHR 3215/4885LMNA 3263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback